William D. Humphries
CIK 1674278 · President, Ortho-Dermatologics · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BHC price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
5 WALNUT GROVE DRIVE SUITE 140
HORSHAM, PA 19044
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACRS | Director | 45,105 | $3.79 | $170.9K | $0 | 13 | 2026-06-08 |
| Clearside Biomedical, Inc. (CLSD) Delisted | Director | 3,403 | $0.35 | $1.2K | $9.9K | 12 | 2024-06-21 |
| STRATA Skin Sciences, Inc. (SSKN) Delisted | Director | 10,972 | $0.15 | $1.6K | $52.8K | 5 | 2023-07-07 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | Director | — | $0.07 | — | $0 | 3 | 2022-06-10 |
| BHC | President, Ortho-Dermatologics | 235,035 | $6.35 | $1.49M | -$2.43M | 11 | 2020-12-08 |
Recent Filings · Page 4 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-03-03 | BHC | Tax (F) | −2,264 | -$55.3K | EDGAR |
| 2020-02-28 | BHC | Grant (A) | +13,506 | $0 | EDGAR |
| 2020-02-24 | BHC | Mixed | +70,162 | -$1.50M | EDGAR |
| 2020-01-07 | BHC | Tax (F) | −14,559 | -$435.6K | EDGAR |
| 2019-08-20 | BHC | Mixed | +61,406 | $650.1K | EDGAR |
| 2019-06-24 | Clearside Biomedical, Inc. (CLSD) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-10 | ACRS | Grant (A) | — | $0 | EDGAR |
| 2019-03-01 | BHC | Grant (A) | +15,221 | $0 | EDGAR |
| 2019-01-07 | BHC | Tax (F) | −13,311 | -$245.9K | EDGAR |
| 2018-06-21 | Clearside Biomedical, Inc. (CLSD) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.